Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05204329 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

Study acronym: MSC Secretome
StatusCompleted
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results posted: Oct 7, 2026 Primary endpoints: 1 to 2 · Eligibility criteria expanded, about 17 words · Secondary endpoints revised (6) · 2 more Show 5 more changesShow less
    • Primary endpoints: 1 to 2
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints revised (6)
    • Publications: details revised at 22 of 22 entries
    • Study description expanded, about 3 words
  2. Re-verified, no change to tracked fieldsv5
  3. Trial status: Recruiting to Completed Enrollment target: estimated 18 to confirmed 9 · Primary and study completion dates changed from estimate of Jul 1, 2025 to Nov 8, 2024 · Site details revised · 1 morev4 Show 4 more changesShow less
    • Enrollment target: estimated 18 to confirmed 9
    • Primary and study completion dates changed from estimate of Jul 1, 2025 to Nov 8, 2024
    • Site details revised
    • Collaborators reordered
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 1, 2023 to Jan 24, 2024 · Study sites: 0 to 1v3 Show 2 more changesShow less
    • Start date changed from estimate of Jun 1, 2023 to Jan 24, 2024
    • Study sites: 0 to 1
  5. Primary and study completion dates: Jan 1, 2025 to Jul 1, 2025 Start date: Dec 1, 2022 to Jun 1, 2023v2 Show 1 more changeShow less
    • Start date: Dec 1, 2022 to Jun 1, 2023
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of topical MSC Secretome eye drops. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use anterior segment Optical Coherence Tomography (OCT)/Scheimpflug Imaging, esthesiometry, and visual analogue scale (VAS) to assess treatment tolerability.
Trial Details
NCT Number NCT05204329
Lead Sponsor University of Illinois at Chicago
Collaborators: National Eye Institute (NEI), National Institutes of Health (NIH)
Conditions Mesenchymal Stromal Cells, Cornea, Corneal Defect, Corneal Epithelium Defect
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov